Literature DB >> 10672239

Bioenergetics in Huntington's disease.

T Grünewald1, M F Beal.   

Abstract

Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder with relentless course and prototypical clinical symptoms. In 1993 HD was associated with an expanded CAG triplet repeat stretch on chromosome 4 in the coding region of its target protein, huntington. The length of the resulting polyglutamine++ extensions correlates with lower age of onset and a higher density of ubiquitin-positive neuronal intranuclear inclusions. Recently it has been proposed that mutant huntington induces progressive neuronal cell death by an apoptotic mechanism. There is strong evidence that disturbances in cellular energy homeostasis and oxidative damage contribute to neurodegeneration. This review will summarize and discuss the current concepts that point towards an involvement of free radical-induced oxidative stress, glutamate excitotoxicity and mitochondrial respiratory chain defects in pathogenesis of HD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10672239     DOI: 10.1111/j.1749-6632.1999.tb07827.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

Review 1.  Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging.

Authors:  L P Mark; R W Prost; J L Ulmer; M M Smith; D L Daniels; J M Strottmann; W D Brown; L Hacein-Bey
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 3.  The mitochondrial permeability transition in neurologic disease.

Authors:  M D Norenberg; K V Rama Rao
Journal:  Neurochem Int       Date:  2007-03-04       Impact factor: 3.921

4.  Inhibitors of metabolism rescue cell death in Huntington's disease models.

Authors:  Hemant Varma; Richard Cheng; Cindy Voisine; Anne C Hart; Brent R Stockwell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 5.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 6.  Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.

Authors:  Peter J Adhihetty; M Flint Beal
Journal:  Neuromolecular Med       Date:  2008-11-13       Impact factor: 3.843

7.  Assessing neuronal bioenergetic status.

Authors:  Stephanie L H Zeiger; Jeannette N Stankowski; BethAnn McLaughlin
Journal:  Methods Mol Biol       Date:  2011

Review 8.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 9.  Shaping the role of mitochondria in the pathogenesis of Huntington's disease.

Authors:  Veronica Costa; Luca Scorrano
Journal:  EMBO J       Date:  2012-03-23       Impact factor: 11.598

Review 10.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.